Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Traws Pharma, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −1 vs. Q2 2025
- Shares held
- 1.30M
- +41.1K (+3.3%) vs. Q2 2025
- Total value
- $2.41M
- +$543.3K (+29.1%) vs. Q2 2025
- New holders
- 3
- 6 more added
- Sold out
- 4
- 1 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRAW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $5.19M |
| Q1 2026 | 28 | $6.62M |
| Q4 2025 | 22 | $3.86M |
| Q3 2025 | 18 | $2.41M |
| Q2 2025 | 19 | $1.87M |
| Q1 2025 | 19 | $3.98M |
| Q4 2024 | 19 | $10.2M |
| Q3 2024 | 12 | $3.80M |
| Q2 2024 | 30 | $1.36M |
| Q1 2024 | 26 | $1.88M |
| Q4 2023 | 27 | $1.35M |
| Q3 2023 | 28 | $1.27M |
| Q2 2023 | 24 | $2.19M |
| Q1 2023 | 25 | $1.04M |
| Q4 2022 | 29 | $1.01M |
| Q3 2022 | 30 | $1.54M |
| Q2 2022 | 32 | $2.36M |
| Q1 2022 | 28 | $3.60M |
| Q4 2021 | 34 | $6.14M |
| Q3 2021 | 37 | $10.5M |
| Q2 2021 | 24 | $10.9M |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Traws Pharma, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 605,531 | $1.12M | 0.03% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 330,000 | $610.5K | 0.00% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 150,000 | $277.5K | 0.01% | +200+0.1% | Added |
| Vanguard Group Inc | 87,259 | $161.4K | 0.00% | +74,086+562.4% | Added |
| Geode Capital Management, LLC | 43,440 | $80.4K | 0.00% | +7,715+21.6% | Added |
| Ikarian Capital, LLC | 28,493 | $52.7K | 0.01% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 22,018 | $40.7K | 0.00% | +5,955+37.1% | Added |
| HRT Financial LP | 12,573 | $23.0K | 0.00% | +12,573 | New |
| XTX Topco Ltd | 10,708 | $19.8K | 0.00% | +10,708 | New |
| BlackRock, Inc. | 9,956 | $18.4K | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 3,528 | $6.53K | 0.00% | +3,468+5,780.0% | Added |
| Morgan Stanley | 719 | $1.33K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 162 | $300 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 102 | $189 | 0.00% | +8+8.5% | Added |
| Vermillion & White Wealth Management Group, LLC | 96 | $178 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 6 | $11 | 0.00% | −3,000−99.8% | Reduced |
| FMR LLC | 2 | $4 | 0.00% | 00.0% | Unchanged |
| Assetmark, Inc | 2 | $4 | 0.00% | +2 | New |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −52,630−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −17,169−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −706−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −102−100.0% | Sold out |